Rapport Therapeutics EBIT

The latest EBIT for RAPP is $-150M as of June 2026. That compares with $-100M in the prior-year period — down 49.7% year over year. That is below the sector sector average of $-63M. Investors often review this figure alongside Rapport Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, RAPP's EBIT moved from $-100M to $-150M — a 49.7% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Rapport Therapeutics's operating scale or balance-sheet position.

Against its sector companies, RAPP currently prints $-150M for EBIT, while the sector average sits near $-63M. That is roughly 143.5% below the sector mean. Large gaps often invite a closer look at Rapport Therapeutics's growth, margins, and balance sheet.

A EBIT figure of $-150M for RAPP is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-63M. Explore the charts below for those layers of context.

After noting RAPP's EBIT ($-150M), review year-over-year change from $-100M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.